Zeneca Pharmaceuticals
Executive Summary
Deputy CEO and Technical Director Tom McKillop, PhD, will become CEO of the Zeneca Group's drug unit effective July 1. He succeeds David Friend, CEO since 1987, who will retire. McKillop, 50, joined ICI Corporate Research Laboratory in 1969, and held a variety of technical positions within ICI leading to his appointment in 1989 as technical director of ICI Pharmaceuticals with international responsibility for R&D and production. In 1992, he became deputy CEO, and he retained the titles when Zeneca was demerged from ICI in June 1993